Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : AAV00212Z
Serotype : AAV Serotype 6 Storage : -80 ℃
Titer: Size:
| Cat. No. | AAV00212Z |
| Description | AAV serotype 6 particles contain GFP under EF1a promoter. |
| Serotype | AAV Serotype 6 |
| Reporter | GFP |
| Applications |
1. Determination of optimal MOI (multiplicity of infection), administration methods etc. 2. Detection of the infection efficiency of the AAV serotype against a specific cell type or tissue. 3. Using reporter genes to visualize the distribution and expression of AAV vectors in live animals, helping assess the biodistribution and persistence of gene delivery. |
| Titer | Varies lot by lot, typically ≥1x10^12 GC/mL |
| Size | Varies lot by lot, for example, 30 μL, 100 μL, 500 μL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Summary | Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots. |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance. |
| Purity | AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE. |
| Sterility | The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth. |
| Transducibility | Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities. |
| Empty vs. Full Capsids | Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods. |
AAV is a single-stranded DNA parvovirus whose genome consists of the rep gene and the cap gene, flanked by two inverted terminal repeats (ITRs). The rep gene encodes Rep78, Rep68, Rep52, and Rep40 from a single ORF, which facilitate AAV genome replication and virion assembly. The three capsid proteins (virion protein 1 (VP1), VP2, and VP3) are produced from a single cap ORF but are regulated by transcription from a rare start codon (ACG) and alternative splicing. Therefore, the C-terminal amino acids of VP1 and VP2 are identical to VP3. In addition, the assembly-activating protein (AAP), which is essential for capsid assembly, is encoded by a frameshifted ORF within the cap gene. All AAV virions are composed of 60 VP subunits with a 1:1:10 ratio of VP1:VP2:VP3. Each subunit has nine variable regions on the virion surface that determine the primary tropism and intracellular trafficking of AAV vectors and are often the domains recognized by neutralizing antibodies (NAbs).
Genetic modification of these variable regions can alter the transduction efficiency of AAV and the ability of NAbs to bind to the virion surface.
In vitro studies support that AAV infects target cells by binding to primary and coreceptors on the cell surface, triggering their entry into endosomes. Following structural changes that expose the N-termini of VP1 and VP2, AAV virions are released from endosomes and accumulate in the perinuclear region of the cell. Once in the nucleus, AAV virions uncoat and release their single-stranded genome, which is converted to a double-stranded DNA (dsDNA) template from which transgenes can be transcribed and translated.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The AAV6-EF1α-GFP's high transduction efficiency in a variety of cell types has consistently delivered reliable and reproducible results. The expression driven by the EF1α promoter is robust, making our imaging studies straightforward and clear.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.